Home » Stocks » EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (EYPT)

Stock Price: $0.700 USD 0.030 (4.48%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 87.65M
Revenue (ttm) 22.75M
Net Income (ttm) -52.18M
Shares Out 125.22M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $0.700
Previous Close $0.670
Change ($) 0.030
Change (%) 4.48%
Day's Open 0.667
Day's Range 0.651 - 0.720
Day's Volume 853,871
52-Week Range 0.650 - 2.690

More Stats

Market Cap 87.65M
Enterprise Value 117.57M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 125.22M
Float 81.77M
EPS (basic) -0.45
EPS (diluted) -0.46
FCF / Share -0.38
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.68M
Short Ratio 1.35
Short % of Float 2.66%
Beta 1.35
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.85
PB Ratio 5.25
Revenue 22.75M
Operating Income -45.64M
Net Income -52.18M
Free Cash Flow -47.77M
Net Cash -29.92M
Net Cash / Share -0.24
Gross Margin 10.15%
Operating Margin -200.58%
Profit Margin -229.30%
FCF Margin -209.95%
ROA -35.43%
ROE -322.13%
ROIC -71.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 2
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$3.33*
(375.71% upside)
Low
1.00
Current: $0.700
High
5.00
Target: 3.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue20.372.967.541.6226.573.472.143.534.9723.05
Revenue Growth587.77%-60.72%365.37%-93.9%664.9%62.06%-39.22%-28.98%-78.46%-
Gross Profit17.682.967.541.6226.573.472.143.534.9723.05
Operating Income-47.86-26.27-18.58-21.776.42-13.49-12.03-25.21-10.009.09
Net Income-56.79-53.17-18.49-21.556.35-13.36-11.90-24.84-8.638.75
Shares Outstanding10446.2335.3431.6229.3827.4423.0420.7919.4918.41
Earnings Per Share-0.54-1.15-0.52-0.680.21-0.49-0.52-1.19-0.440.46
Operating Cash Flow-56.70-21.91-20.49-16.3210.30-10.67-8.75-9.00-3.179.90
Capital Expenditures-0.21-0.11-0.11-0.11-0.16-0.17-0.07-0.41-0.13-0.02
Free Cash Flow-56.91-22.02-20.60-16.4310.14-10.84-8.81-9.41-3.309.88
Cash & Equivalents22.3638.9317.0529.1428.6918.4310.2714.5724.1317.57
Total Debt50.1217.31--------
Net Cash / Debt-27.7621.6217.0529.1428.6918.4310.2714.5724.1317.57
Assets72.9771.6718.6831.6232.3722.6716.2520.6047.1143.01
Liabilities64.6459.985.3410.749.007.758.556.969.689.97
Book Value8.3311.6913.3420.8823.3714.927.7013.6437.4333.04
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name EyePoint Pharmaceuticals, Inc.
Country United States
Employees 84
CEO Nancy Sue Lurker

Stock Information

Ticker Symbol EYPT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EYPT
IPO Date January 27, 2005

Description

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.